Fiduciary Management Inc. WI grew its stake in shares of Mednax, Inc (NYSE:MD) by 132.6% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,029,973 shares of the company’s stock after purchasing an additional 587,248 shares during the period. Fiduciary Management Inc. WI owned approximately 1.10% of Mednax worth $62,179,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Pacer Advisors Inc. boosted its position in shares of Mednax by 3.2% during the 1st quarter. Pacer Advisors Inc. now owns 1,795 shares of the company’s stock worth $125,000 after purchasing an additional 55 shares in the last quarter. Commonwealth Bank of Australia boosted its position in shares of Mednax by 15.3% during the 2nd quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock worth $132,000 after purchasing an additional 293 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in shares of Mednax by 8.7% during the 1st quarter. Daiwa Securities Group Inc. now owns 2,500 shares of the company’s stock worth $173,000 after purchasing an additional 200 shares in the last quarter. Commerzbank Aktiengesellschaft FI boosted its position in shares of Mednax by 8.3% during the 1st quarter. Commerzbank Aktiengesellschaft FI now owns 3,442 shares of the company’s stock worth $239,000 after purchasing an additional 265 shares in the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. purchased a new stake in shares of Mednax during the 2nd quarter worth $217,000.
In related news, insider John C. Pepia sold 3,000 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total value of $128,550.00. Following the completion of the transaction, the insider now owns 35,569 shares in the company, valued at approximately $1,524,131.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.40% of the company’s stock.
Several equities research analysts have commented on MD shares. BidaskClub upgraded shares of Mednax from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Stephens upgraded shares of Mednax from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $55.00 to $68.00 in a research report on Thursday, June 22nd. Jefferies Group LLC restated a “hold” rating and set a $53.00 target price (up from $50.00) on shares of Mednax in a research report on Thursday, July 6th. Robert W. Baird restated a “hold” rating and set a $47.00 target price on shares of Mednax in a research report on Sunday, September 3rd. Finally, ValuEngine lowered shares of Mednax from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $59.88.
Mednax, Inc (NYSE MD) traded down 0.33% during midday trading on Friday, hitting $42.90. 2,071,455 shares of the company traded hands. The stock has a market cap of $3.95 billion, a P/E ratio of 13.66 and a beta of 0.40. The stock has a 50 day moving average of $43.51 and a 200 day moving average of $57.01. Mednax, Inc has a 12-month low of $41.20 and a 12-month high of $72.13.
Mednax (NYSE:MD) last released its quarterly earnings results on Friday, July 28th. The company reported $0.85 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.81 by $0.04. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The business had revenue of $843.00 million during the quarter, compared to analyst estimates of $849.49 million. During the same quarter last year, the company posted $1.03 EPS. Mednax’s revenue for the quarter was up 9.2% on a year-over-year basis. Equities research analysts predict that Mednax, Inc will post $3.31 EPS for the current fiscal year.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.